Overview

Administration of Dexmedetomidine Guided by Entropy/SPI Reduce

Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine, a selective alpha2-adrenergic agonist is known to reduce propofol and opioid requirements due to its sedative and analgesic properties. However, until now, there has been studies based on indirect measures such as hemodynamics. Entropy shows to quantify the level of consciousness by EEG and Surgical pleth index(SPI) allows to predict the effect of pain stimuli and analgesic therapy by the index of the nociception-anti-nociception balance. The investigators analyzed quantitatively the requirements of propofol and remifentanil under continuous infusion of dexmedetomidine when using entropy and SPI.
Phase:
N/A
Details
Lead Sponsor:
Gangnam Severance Hospital
Treatments:
Dexmedetomidine